<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02195973</url>
  </required_header>
  <id_info>
    <org_study_id>F140214007 (UAB 1357)</org_study_id>
    <secondary_id>000505867</secondary_id>
    <nct_id>NCT02195973</nct_id>
  </id_info>
  <brief_title>Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer</brief_title>
  <official_title>Phase IB Trial of LDE225 and Weekly Paclitaxel in Recurrent Platinum Resistant Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if a new drug, LDE225, is safe and has beneficial&#xD;
      effects when combined with paclitaxel in women with platinum resistant ovarian cancer.&#xD;
      Platinum resistant ovarian cancer refers to recurrent ovarian cancer that has undergone&#xD;
      chemotherapy inclusive of a platinum compound (e.g. carboplatin or cisplatin).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovarian cancer remains the deadliest gynecologic cancer with a fairly low long-term cure&#xD;
      rate. LDE225 is a new type of drug that inhibits or blocks a pathway responsible for cancer&#xD;
      cell growth. LDE225 is an investigational drug that has been used either solely or in&#xD;
      combination with chemotherapy in other types of cancer but not in ovarian cancer. Research&#xD;
      evidence suggests that by combining LDE225 and paclitaxel together, ovarian cancer cells may&#xD;
      become more responsive to treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">September 30, 2017</completion_date>
  <primary_completion_date type="Actual">December 10, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of weekly paclitaxel + LDE225 treatment</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Safety of weekly paclitaxel and LDE225 treatment in patients with recurrent, platinum-resistant ovarian adenocarcinoma will be monitored by physical exams, review of adverse events, and laboratory studies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of toxicities</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Assessment of toxicity will be performed using the National Cancer Institute Common Toxicity Criteria version 4.03.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optimal dose of LDE225 with paclitaxel</measure>
    <time_frame>6 months</time_frame>
    <description>The maximum tolerated dose and dose-limiting toxicities of weekly paclitaxel and daily LDE225 will be determined from laboratory tests on blood collected one to two times each cycle.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Recurrent Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel + LDE225</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive intravenous paclitaxel on days 1, 8, and 15 every 28 days (3 weeks on followed by one week off). This constitutes one cycle. in addition to the paclitaxel oral LDE225 will be taken daily. Dosages of each drug will vary according to the study cohort and phase. The study consists of six cycles of treatment followed by clinic visits every 2-3 months for up to two years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDE225</intervention_name>
    <description>After six cycles of weekly paclitaxel and LDE225, patients with a clinically beneficial response may be continued on weekly paclitaxel alone until disease progression.</description>
    <arm_group_label>Paclitaxel + LDE225</arm_group_label>
    <other_name>Sonidegib (LDE225)</other_name>
    <other_name>Taxol (Paclitaxel)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma&#xD;
             Histologic confirmation of the original primary tumor is required&#xD;
&#xD;
          -  Papillary serous, endometrioid, clear cell, undifferentiated and mixed histologies&#xD;
&#xD;
          -  Platinum resistant or refractory disease as per standard clinical and Gynecologic&#xD;
             Oncology Group definition. Patients have had a treatment-free interval of less than 6&#xD;
             months from last platinum-based treatment to recurrence or progression during platinum&#xD;
             based therapy&#xD;
&#xD;
          -  Patients must have received at least one-prior platinum based chemotherapy regimen, to&#xD;
             include cisplatin, carboplatin or other organoplatinum compound, for treatment of&#xD;
             primary or recurrent ovarian, fallopian tube or primary peritoneal cancer&#xD;
&#xD;
          -  Patients must have received a taxane as part of their prior treatment&#xD;
&#xD;
          -  Measurable disease is required. By definition, measurable disease is at least one&#xD;
             lesion that can be accurately measured in at least one dimension with the longest&#xD;
             dimension to be recorded. Each lesion must be ≥ 20 mm when measured by conventional&#xD;
             techniques, including palpation, plain x-ray, CT, MRI or ≥ 10 mm when measured by&#xD;
             spiral CT imaging&#xD;
&#xD;
          -  Patients must have one target lesion to be utilized in order to assess response per&#xD;
             RECIST criteria&#xD;
&#xD;
          -  ECOG Performance statuses of 0, 1, or 2&#xD;
&#xD;
          -  Adequate organ function as evidenced by:&#xD;
&#xD;
               1. Hematology: WBC ≥3.0 x 10^9/L; ANC ≥1.5 x 10^9/L; Platelets ≥100 x 10^9/L&#xD;
&#xD;
               2. Renal function: Creatinine less than or equal to 1.5 x institutional upper limit&#xD;
                  of normal (ULN) or 24-hour clearance greater than or equal to 50 mL/min&#xD;
&#xD;
               3. Hepatic function: Bilirubin ≤ 1.5 x ULN and ALT, SGOT and alkaline phosphatase ≤&#xD;
                  2.5 x ULN&#xD;
&#xD;
               4. Plasma creatine phosphatase (CK) less than 1.5 x ULN&#xD;
&#xD;
               5. Serum creatinine less than or equal to 1.5 x ULN or 24-hour clearance greater&#xD;
                  than or equal to 50 mL/min&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Female patients of any ethnic group. Female patients must be surgically sterile,&#xD;
             postmenopausal (no menses for at least one year), or using medically approved method&#xD;
             of contraception (excluding rhythm, withdraw or abstinence)&#xD;
&#xD;
          -  Age greater than or equal to 19&#xD;
&#xD;
          -  Recovery from effects of any recent surgery, chemotherapy and/or radiation&#xD;
&#xD;
               1. No evidence of active infection requiring antibiotic therapy&#xD;
&#xD;
               2. Hormonal therapy being utilized, as an anti-neoplastic treatment must be&#xD;
                  discontinued at least one week prior to study entry. Hormonal replacement therapy&#xD;
                  for symptom management is allowed&#xD;
&#xD;
               3. Any prior therapy directed at the malignancy including biologic or immunologic&#xD;
                  agents, must have be discontinued at least three weeks prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with pathology demonstrating mucinous, carcinosarcoma or low malignant&#xD;
             potential tumor histology are excluded. In addition, non-ovarian malignancies,&#xD;
             malignant germ cell or stromal tumors are also excluded&#xD;
&#xD;
          -  Previous or concurrent malignancies at other sites within the last 5 years, with the&#xD;
             exception of in situ carcinoma of the cervix and adequately treated basal cell&#xD;
             carcinoma or squamous cell carcinoma of the skin. In addition, patients with prior or&#xD;
             concomitant, based on hysterectomy, Stage IA endometrial adenocarcinoma with less than&#xD;
             3 mm depth on invasion, absence of lymphovascular space invasion and absence of grade&#xD;
             3, papillary serous or clear cell histology are allowed&#xD;
&#xD;
          -  Patients with prior radiation to the abdominal cavity or pelvis are excluded&#xD;
&#xD;
          -  Patients unable to take oral drugs or with lack of physical integrity of the upper&#xD;
             gastrointestinal tract or known malabsorption syndromes&#xD;
&#xD;
          -  Patients who have previously been treated with systemic sonidegib (LDE225) or with&#xD;
             other Hh pathway inhibitors&#xD;
&#xD;
          -  Serious concomitant illness including but not limited to: uncontrolled diabetes&#xD;
             mellitus, dementia, active infection (including HIV infection) requiring IV or oral&#xD;
             antibiotics and psychiatric illness and/or other uncontrolled medical conditions which&#xD;
             may preclude compliance with study protocol&#xD;
&#xD;
          -  Patients who have neuromuscular disorder (e.g. inflammatory myopathies, muscular&#xD;
             dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on&#xD;
             concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as&#xD;
             HMG CoA inhibitors (statins), clofibrate and gemfibrozil, and the cannot be&#xD;
             discontinued at least 2 weeks prior to starting sonidegib treatment. If it is&#xD;
             essential that the patient remain on a statin to control hyperlididemia, only&#xD;
             pravastatin may be used with extra caution&#xD;
&#xD;
          -  Patients who are planning on embarking on a new strenuous exercise regimen after&#xD;
             initiation of study treatment. Muscular activities, such as strenuous exercise, that&#xD;
             can result in significant increases in plasma CK levels should be avoided whilst on&#xD;
             sonidegib treatment&#xD;
&#xD;
          -  Patients who have taken part in an experimental drug study within 4 weeks or 5&#xD;
             half-lives, whichever is longer, of initiating treatment with sonidegib&#xD;
&#xD;
          -  Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted&#xD;
             therapy or radiotherapy) concurrently or within 2 weeks of starting treatment with&#xD;
             sonidegib&#xD;
&#xD;
          -  Peripheral Neuropathy of NCI-CTC (National Cancer Institute-Common Toxicity Criteria)&#xD;
             grade greater than or equal to 2&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant heart disease, including any one&#xD;
             of the following:&#xD;
&#xD;
               1. Angina pectoris within 3 months&#xD;
&#xD;
               2. Acute myocardial infarction within 3 months&#xD;
&#xD;
               3. QTcF &gt; 470 msec on the screening ECG&#xD;
&#xD;
               4. A past medical history of clinically significant ECG abnormalities or a family&#xD;
                  history of prolonged QT-interval syndromes&#xD;
&#xD;
               5. Other clinically significant heart disease (e.g. congestive heart failure,&#xD;
                  uncontrolled hypertension, history of labile hypertension, or history of poor&#xD;
                  compliance with an antihypertensive regimen)&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive hCG laboratory test (&gt;5 mIU/mL)&#xD;
&#xD;
          -  Patients who are not willing to apply highly effective contraception during the study&#xD;
             and through the duration as defined below after the final dose of study treatment&#xD;
&#xD;
             a. Women of childbearing potential defined as all women physiologically capable of&#xD;
             becoming pregnant. Must use highly effective contraception during the study and&#xD;
             through 20 months after the final dose of study treatment. Highly effective&#xD;
             contraception is defined as either:&#xD;
&#xD;
               1. Total abstinence: When this is in line with the preferred and usual lifestyle of&#xD;
                  the patient. Periodic abstinence (e.g. calendar, ovulation, symptothermal,&#xD;
                  post-ovulation methods) and withdrawal are not acceptable methods of&#xD;
                  contraception&#xD;
&#xD;
               2. Sterilization: Patient has had surgical bilateral oophorectomy (with or without&#xD;
                  hysterectomy) or tubal ligation at least six weeks before taking study treatment.&#xD;
                  In case of oophorectomy alone, only when the reproductive status of the woman had&#xD;
                  been confirmed by follow- up hormone level assessment&#xD;
&#xD;
               3. Male partner sterilization (with the appropriate post-vasectomy documentation of&#xD;
                  the absence of sperm in the ejaculate). For female study patients, the&#xD;
                  vasectomized male partner should be the sole partner for that patient&#xD;
&#xD;
               4. Use a combination of the following (both a + b):&#xD;
&#xD;
                    1. Placement of a non-hormonal intrauterine device (IUD) or non- hormonal&#xD;
                       intrauterine system (IUS)&#xD;
&#xD;
                    2. Barrier method of contraception: Condom or occlusive cap (diaphragm or&#xD;
                       cervical vault caps) with spermicidal foam/gel/film/cream/vaginal&#xD;
                       suppository.&#xD;
&#xD;
                       Note: Hormonal contraception methods (e.g. oral, injected, implanted) are&#xD;
                       not allowed as it cannot be ruled out that the study drug decreases the&#xD;
                       effectiveness of hormonal contraception.&#xD;
&#xD;
                       Note: Women are considered post-menopausal and not child bearing potential&#xD;
                       if they have had 12 months of natural (spontaneous) amenorrhea with an&#xD;
                       appropriate clinical profile (e.g. age appropriate, history of vasomotor&#xD;
                       symptoms) or six months of spontaneous amenorrhea with serum FSH levels &gt;40&#xD;
                       mIU/mL and estradiol &lt;20 pg/mL or have had surgical bilateral oophorectomy&#xD;
                       (with or without hysterectomy) at least six week ago. In the case of&#xD;
                       oophorectomy alone, only when the reproductive status of the woman has been&#xD;
                       confirmed by follow up hormone level assessment is she considered not of&#xD;
                       child bearing potential.&#xD;
&#xD;
          -  History of hypersensitivity to paclitaxel&#xD;
&#xD;
          -  Mental condition rendering the subject unable to understand the nature, scope, and&#xD;
             possible consequences of the study&#xD;
&#xD;
          -  Patients who are receiving treatment with medications known to be moderate and strong&#xD;
             inhibitors or inducers of CYP3A4/5 or drugs metabolized by CYP2B6 or CYP2C9 that have&#xD;
             narrow therapeutic index, and that cannot be discontinued before starting treatment&#xD;
             with sonidegib. Medications that are strong CYP3A4/5 inhibitors should be discontinued&#xD;
             at least 7 days and strong CYP3A/5 inducers for at least 2 weeks prior to starting&#xD;
             treatment with sonidegib&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles A Leath, III, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2014</study_first_posted>
  <last_update_submitted>June 14, 2018</last_update_submitted>
  <last_update_submitted_qc>June 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Charles A Leath, III, MD, MSPH</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>platinum resistant</keyword>
  <keyword>LED225</keyword>
  <keyword>Sonidegib</keyword>
  <keyword>Paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02195973
org study id: F140214007 (UAB 1357)
secondary id: 000505867
nct id: NCT02195973
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated device: No
The purpose of this study is to find out if a new drug, LDE225, is safe and has beneficial
      effects when combined with paclitaxel in women with platinum resistant ovarian cancer.
      Platinum resistant ovarian cancer refers to recurrent ovarian cancer that has undergone
      chemotherapy inclusive of a platinum compound (e.g. carboplatin or cisplatin).
Ovarian cancer remains the deadliest gynecologic cancer with a fairly low long-term cure
      rate. LDE225 is a new type of drug that inhibits or blocks a pathway responsible for cancer
      cell growth. LDE225 is an investigational drug that has been used either solely or in
      combination with chemotherapy in other types of cancer but not in ovarian cancer. Research
      evidence suggests that by combining LDE225 and paclitaxel together, ovarian cancer cells may
      become more responsive to treatment.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Safety of weekly paclitaxel + LDE225 treatment
time frame: up to 2 years
description: Safety of weekly paclitaxel and LDE225 treatment in patients with recurrent, platinum-resistant ovarian adenocarcinoma will be monitored by physical exams, review of adverse events, and laboratory studies.
measure: Assessment of toxicities
time frame: up to 2 years
description: Assessment of toxicity will be performed using the National Cancer Institute Common Toxicity Criteria version 4.03.
measure: Optimal dose of LDE225 with paclitaxel
time frame: 6 months
description: The maximum tolerated dose and dose-limiting toxicities of weekly paclitaxel and daily LDE225 will be determined from laboratory tests on blood collected one to two times each cycle.
arm group label: Paclitaxel + LDE225
arm group type: Experimental
description: Patients will receive intravenous paclitaxel on days 1, 8, and 15 every 28 days (3 weeks on followed by one week off). This constitutes one cycle. in addition to the paclitaxel oral LDE225 will be taken daily. Dosages of each drug will vary according to the study cohort and phase. The study consists of six cycles of treatment followed by clinic visits every 2-3 months for up to two years.
intervention type: Drug
intervention name: LDE225
description: After six cycles of weekly paclitaxel and LDE225, patients with a clinically beneficial response may be continued on weekly paclitaxel alone until disease progression.
arm group label: Paclitaxel + LDE225
other name: Sonidegib (LDE225)
other name: Taxol (Paclitaxel)
criteria: 
gender: Female
minimum age: 19 Years
maximum age: N/A
healthy volunteers: No
last name: Charles A Leath, III, MD, MSPH
role: Principal Investigator
affiliation: University of Alabama at Birmingham
facility: 
country: United States
responsible party type: Principal Investigator
investigator affiliation: University of Alabama at Birmingham
investigator full name: Charles A Leath, III, MD, MSPH
investigator title: Associate Professor
mesh term: Ovarian Neoplasms
mesh term: Carcinoma, Ovarian Epithelial
mesh term: Recurrence
mesh term: Paclitaxel
sharing ipd: No